• Product NameeIF4E(Phospho-Ser209) Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
• ApplicationsWB IHC IF
• Species ReactivityHu
• SpecificityThe antibody detects endogenous level of eIF4E only when phosphorylated at serine 209.
• Immunogen TypePeptide-KLH
• Immunogen DescriptionPeptide sequence around phosphorylation site of serine 209 (S-G-S(p)-T-T) derived from Human eIF4E.
• Target NameeIF4E
• ModificationPhospho
• Alternative Names    mRNA cap-binding protein; eIF-4F 25 kDa subunit;
• Accession No. Swiss-Prot: P06730
  NCBI Protein: NP_001124150.1
• UniprotP06730
• Gene ID1977;
• Concentration 1.0mg/ml
• Formulation Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Storage Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

• Predicted MW: 25kd
  Western blotting: 1:500~1:1000
  Immunohistochemistry: 1:50~1:100
  Immunofluorescence: 1:100~1:200

Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures.

Li BD, et al. (1998) Ann Surg; 227(5): 756-763
Altmann M, et al. (1989) Nucleic Acids Res; 17(18): 7520
De Gregorio E, et al. (2001) RNA; 7(1): 106-113
Gu W, et al. (2004) Nucleic Acids Res; 32(15): 4448-4461

• Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using eIF4E(Phospho-Ser209) Antibody #11233(left) or the same antibody preincubated with blocking peptide(right).
• Immunofluorescence staining of methanol-fixed MCF cells using eIF4E(Phospho-Ser209) Antibody #11233.
• Western blot analysis of extracts from SK-BR-3 cells, untreated or insulin and EGF treated, and pretreated with U0126 cells, using eIF4E (Phospho-Ser209) Antibody #11233.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting